08:48 AM EST, 12/05/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) on Thursday said updated and promising clinical data from its Phase 1/2 ABILITY-1 study were presented today at a conference in Naples, Italy.

The oral presentation included new data highlighting the first complete response (CR) in the combination dose escalation phase of the study in a 70-year-old patient with advanced anal squamous cell carcinoma (anal SCC). The patient, which had previously progressed on two other lines of treatment, achieved a 100% reduction of all measurable target and non-target lesions by Week 8.

"Achieving a complete response in a patient with anal squamous cell carcinoma, a cancer with historically low immunotherapy response rates, demonstrates MDNA11's ability to reinvigorate the immune system and tackle difficult-to-treat tumors," said Dr Fahar Merchant, CEO.

The company also presented other data from the study, including one patient with melanoma remaining tumour-free at week 63 and another patient with pancreatic cancer who is off all anti-cancer therapy for 11 months after completing the study.

Medicenna will share additional clinical data at medical conferences in the first half of next year.